Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials

Xing Li1, Bao-En Shan2, Juan Wang1, Lian-Ping Xing3, Xiao-Jin Guo1, Yue-Hua Zhang1, Peng-Hui Shi1, Zhi-Yu Wang1*

1 Department of Biotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China, 2 Centre of Scientific Research, Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China, 3 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States of America

Abstract

**Background:** Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) cetuximab and panitumumab have emerged as an effective targeted therapy in the treatment of cancer patients, but the overall incidence and risk of fatal adverse events (FAEs) associated with these agents is still unclear.

**Methods:** Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to May 31, 2013 were searched to identify relevant studies. Eligible studies included prospective randomized controlled trials evaluating MoAbs in cancer patients with adequate data on FAEs. Statistical analyses were conducted to calculate the summary incidence, odds ratio and 95% confidence intervals (CIs) by using either random effects or fixed effect models according to the heterogeneity of included studies.

**Results:** A total of 14,776 patients with a variety of solid tumors from 21 clinical trials were included in our analysis. The overall incidence of MoAbs associated FAEs was 1.7% (95%CI: 1.1–2.5%), and the incidence of cetuximab-related FAEs was higher than that of panitumumab (2.0% versus 0.9%). Compared with the controls, the use of MoAbs was associated with a significantly increased risk of FAEs, with an OR of 1.37 (95%CI: 1.04–1.81, p=0.024).

Subgroup analysis based on EGFR-MoAbs drugs, phase of trials and tumor types demonstrated a tendency to increase the risk of FAEs, but the risk did not increase in breast cancer, esophagus cancer and phase II trials.

**Conclusions:** With present evidence, the use of EGFR-MoAbs is associated with an increased risk of FAEs in patients with advanced solid tumors.

Introduction

Epidermal growth factor receptors (EGFR) are a large family of receptor tyrosine kinases which are overexpressed in many types of cancer[1], including breast[2], lung[3,4], esophageal[5], and head and neck[6]. EGFR and its family members are the major contributors of a complex signaling cascade that modulates proliferation, anti-apoptosis, differentiation, adhesion, migration and survival of cancer cells[7]. Due to their multidimensional role in the progression of cancer, EGFR and its family members have emerged as attractive candidates for anticancer therapy. Currently, there are two classes of anti-EGFR agents: the monoclonal antibodies (cetuximab, panitumumab) and small-molecule tyrosine kinase inhibitors (gefitinib, erlotinib). Cetuximab (C) is a chimeric monoclonal antibody (MoAb) that binds to the EGFR and blocks the EGFR signaling cascade, thus inhibiting the growth of the tumor[8]. Panitumumab (P) is an anti-EGFR MoAb which, like C, binds to the EGFR to prevent ligand binding and inhibits the subsequent activation of key downstream signaling molecules involved in

Citation: Li X, Shan B-E, Wang J, Xing L-P, Guo X-J, et al. (2013) Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials. PLoS ONE 8(11): e81897. doi:10.1371/journal.pone.0081897

Editor: Alan Landay, Rush University, United States of America

Received July 27, 2013; Accepted October 14, 2013; Published November 28, 2013

Copyright: © 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by grants from the National Natural Science Foundation of China (81202037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

* E-mail: Wangzhiyu201307@163.com
tumorigenesis[9]. Erlotinib and gefitinib are oral small molecules designed to selectively inhibit the phosphorylation of EGFR intracellular kinase domain [10,11]. In addition, these four drugs have shown clinical benefits in the treatment of many types of malignancy and have been approved for use in cancer therapy by the United States Food and Drug Administration (FDA)[10-13].

Fatal adverse events (FAEs) are defined as deaths that are usually secondary to the use of the pharmaceutical agent[14]. Patients with cancer may be at an increased risk because of the progressive nature of malignancy as well as the adverse events (AEs) profiles of chemotherapeutic agents. As a result, determining the incidence and risk of drugs related FAEs is important for closely monitoring and planning appropriate strategies to limit their effects. A previous meta-analysis includes a total of 13,827 patients with various advanced solid tumors from 22 phase III RCTs that finds the overall incidence of EGFR-TKIs (gefitinib and erlotinib) related FAEs is 1.9% (95%CI: 1.2-2.9%), and the use of EGFR-TKIs does not increase the risk of FAEs with an RR of 0.99 (95%CI: 0.70-1.41, p=0.97)[15]. However, the risk of FAEs associated with EGFR-MoAbs has not been well determined. Although a recent meta-analysis shows that cetuximab does not significantly increase the risk of FAEs in colorectal cancer (OR, 1.41; 95% CI, 0.99-2.03)[16], this meta-analysis is limited to only nine studies examining cetuximab-related FAEs in colorectal cancer. In addition, the incidence and risk of FAEs associated with panitumumab, a newly approved anti-EGFR MoAbs, has not been assessed. Here, we conduct this meta-analysis of RCTs to determine the incidence and risk of FAEs associated with the clinical use of EGFR-MoAbs cetuximab and panitumumab.

Materials and Methods

Data source

Study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [17,18]. We searched the Pubmed (data from 1966 to May 2013), EMBASE (data from 1980 to May 2013), and Cochrane library databases (up to May 2013) for relevant trials. The search was conducted by using the keywords “cetuximab”, “C-255”, “Erbitux”, “panitumumab”, “Vectibix”, “randomized”, “cancer” and was limited to human studies and prospective randomized controlled clinical trials published in English. Abstracts presented at the annual meetings of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) (from 2001 to 2013) were also searched manually using the same keywords to identify relevant clinical trials; Additionally, we searched the clinical trial registration website (http://www.ClinicalTrials.gov) to obtain information on the registered randomized controlled trials (RCTs); however, only trials published in peer-reviewed publications, in full manuscript form, were included. Each publication was reviewed and in cases of duplicate publication only the most complete, recent, and updated report of the clinical trial was included in the meta-analysis.

Study selection

The goal of this study was to determine the incidence of EGFR-MoAbs associated FAEs and establish the association between treatment with EGFR-MoAbs and the risk of FAEs. Thus, Phase I trials were omitted due to multiple dose level and limited sample sizes. Clinical trials that met the following criteria were included in the meta-analysis: (1) prospective randomized controlled II and III trials of patients with cancer; (2) participants assigned to treatment with approved EGFR-MoAbs cetuximab and panitumumab (alone or in combination); and (3) available data on FAEs.

Data extraction and clinical endpoints

Data extraction was conducted independently by two investigators (L.X. and W.Z.Y.), and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was extracted: author’s name, year of publication, trial phase, number of enrolled subjects, treatment arms, number of patients in treatment and control groups when available, underlying malignancy, median age, median treatment duration, median progression-free survival, adverse outcomes of interest (fatal adverse events), name and dosage of EGFR-MoAbs and the dosing schedules used. The primary end point of the analysis was treatment emergent, non-disease-related, fatal adverse events. Adverse events were defined as per versions two or three of the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) criteria[19]. Both versions are similar in defining fatal adverse events as grade five, though version three requires attribution to specific adverse events while version two did not have such requirements. We excluded events that were reported as related to disease progression, but included all events with unspecified attribution and included events regardless of attribution to treatment provided that they were not related to disease progression.

Statistical analysis. We extracted the number of patients experiencing a FAEs and the total number of patients being treated with the study drug to calculate incidence. For studies with a control group in the same trial, we also calculated and compared the odds ratio (OR) of FAEs. We used the Peto method to calculate ORs and 95% confidence intervals (CIs) because this method provides the best CI coverage and is more powerful and relatively less biased than the fixed or random-effects analysis when dealing with low event rates[20]. To assess the stability of results, sensitivity analysis was carried out by sequential omission of individual studies. Additionally, to test whether effect sizes were moderated by differences in length of treatment, we have carried out meta-regressions with difference in median length of experimental treatments (expressed in weeks) as predictor and odds ratio as dependent variable. Between-study heterogeneity was estimated using the $\chi^2$-based Q test and $I^2$ statistic[21]. The random-effects model was used in presence of heterogeneity, and the fixed-effects model in its absence. We also conducted the following prespecified subgroup analyses: different EGFR-MoAbs, phase of trials and tumor types. In addition, we calculated ORs for each study using an empirical continuity correction in all studies with zeros to investigate the sensitivity...
Results

Our search yielded 913 publications describing the use of cetuximab and panitumumab, and 21 RCTs were finally included in the meta-analysis. The selection process is summarized in Figure 1. In total, 14,776 patients were investigated in these trials and they had a variety of cancers: colorectal cancer (eleven trials)[24-34], non-small-cell lung cancer (five trials)[35-39], head and neck cancer (two trials)[40,41], esophagus carcinoma (one trial)[42], pancreatic cancer (one trial)[43] and breast cancer (one trial)[44]. Sample size were in the range of 62 to 2686 patients, with fourteen trials including >400 patients each. According to the inclusion criteria of each trial, patients were required to have an adequate renal, hepatic and hematologic function. The median age of study participants was in the range of 52–66 years (some studies only reported the mean age). Table 1 reports the study and patient characteristics for the included trials.

Incidence of FAEs

For the incidence of FAEs, all MoAbs treatment arms were included, representing a total of 7841 patients. By using a random-effects model (heterogeneity test: $I^2=75\%$; $p<0.001$), the incidence of FAEs due to MoAbs was determined to be 1.7% (95%CI: 1.1-2.5%). The highest incidence was observed in a phase II trial of cetuximab in non-small-cell lung cancer [39], with a combined incidence of 5.7% (95%CI: 1.8-16.1%). No FAEs were observed in six trials[24,35,37,40,42,44]. When stratified by each MoAbs, the incidence was 2.0% (95%CI: 1.3-3.2%) for cetuximab, 0.9% (95%CI: 0.5-1.7%) for panitumumab (Figure 2). The incidence of FAEs associated
Table 1. Baseline characteristics of the 21 trials included in the meta-analysis (n=14,776).

| Histology       | Authors/ year/phase | Patients enrolled | Treatment Arm | Median treatment duration (years) | Median ageduration (weeks) | Median PFS/TTTP (months) | Median OS (months) | No. for analysis | No. of FAEs |
|-----------------|---------------------|-------------------|---------------|-----------------------------------|---------------------------|------------------------|-------------------|-----------------|-------------|
| CRC             | Van Cutsem E. et al/2007/III | 463                | P+BSC         | 62                                 | NR                        | 8                      | NR                | 229             | 0           |
|                 |                      |                   | BSC           | 63                                 | NR                        | 7.3 weeks              | NR                | 234             | 0           |
|                 | Sorensen A.F. et al/2008/III | 1298              | C+CT+11       | 61                                 | 14                        | 4                      | 10.7              | 638             | 5           |
|                 |                      |                   | CPT+11        | 62                                 | 13.1                      | 2.6                    | 10                | 629             | 2           |
|                 | Bokemeyer C. et al/2009/III | 341               | C+FOLFOX-4    | 62                                 | 24                        | 7.2                    | NR                | 170             | 9           |
|                 |                      |                   | FOLFOX-4      | 60                                 | NR                        | 7.2                    | NR                | 168             | 5           |
|                 | Hecht J.R. et al/2009/III | 1053              | P +L-OHP+Bev  | 61                                 | NR                        | 10                     | 19.4              | 407             | 5           |
|                 |                      |                   | L-OHP+Bev     | 62                                 | NR                        | 11.4                   | 24.5              | 397             | 0           |
|                 |                      |                   | P+Bev+CPT+11  | 60                                 | NR                        | 10.1                   | 20.7              | 111             | 2           |
|                 |                      |                   | Bev+CPT+11    | 59                                 | NR                        | 11.7                   | 20.5              | 113             | 0           |
|                 | Van Cutsem E. et al/2009/III | 1217              | C+ FOLFIRI    | 61                                 | 25                        | 8.9                    | 19.9              | 600             | 25          |
|                 |                      |                   | FOLFIRI       | 61                                 | 26                        | 8                      | 18.6              | 602             | 24          |
|                 | Tol J et al/2009/III | 755               | C+ capecitabine +L-OHP+Bev | 62 | 24 | 9.4 | 19.4 | 366 | 10 |
|                 |                      |                   | Capcitabine +L-OHP+Bev | 62 | 28 | 10.8 | 20.3 | 366 | 7 |
|                 | Maugan T.S. et al/2011/III | 1630              | C +chemotherapy | 63 | NR | 8.6 | 17 | 815 | 9 |
|                 |                      |                   | chemotherapy   | 63                                 | NR                        | 8.6                    | 17.9              | 815             | 10          |
|                 | Alberts S.R. et al/2012/III | 2686              | C+ mFOLFOX6   | NR                                 | NR                        | NR                     | NR                | 1349            | 8           |
|                 |                      |                   | mFOLFOX6      | NR                                 | NR                        | NR                     | NR                | 1337            | 3           |
|                 | Saltz L. et al/2012/III | 247               | C +Bev+FOLFOX | 63.2                               | 24                        | 8.3                    | 19.5              | 123             | 6           |
|                 |                      |                   | Bev+FOLFOX    | 61.2                               | NR                        | 11                     | 21.3              | 124             | 4           |
|                 | Douillard J.Y. et al/2010/III | 1183              | P+FOLFOX4     | NR                                 | NR                        | 9.6                    | 23.9              | 539             | 6           |
|                 |                      |                   | FOLFOX4       | NR                                 | NR                        | 8.6                    | 19.7              | 545             | 5           |
|                 | Peeters M. et al/2010/III | 1186              | P+FOLFIRI     | NR                                 | NR                        | 5.9                    | 14.5              | 539             | 2           |
|                 |                      |                   | FOLFIRI       | NR                                 | NR                        | 3.9                    | 12.5              | 540             | 4           |
| NSCLC           | Butts C.A. et al/2007/II | 131               | C+ GEM+platinum | 66 | 15.1 | 5.09 | 11.99 | 65 | 0 |
|                 |                      |                   | GEM+platinum  | 64                                 | 13.0                      | 4.21                   | 9.26              | 66              | 0           |
|                 | Lienbaum R. et al/2009/III | 64                | C+PTX         | NR                                 | 16                        | 3.4                    | 3.4               | 30              | 1           |
|                 |                      |                   | bortezomib+PTX| NR                                 | 8                        | 1.9                    | 1.9               | 29              | 1           |
|                 | Pirker R.et al/2009/III | 1125              | C+ chemotherapy | 59 | 18 | 11.3 | 548 | 15 |
|                 |                      |                   | chemotherapy   | 60                                 | 14                        | NR                     | 10.1              | 562             | 10          |
|                 | Lynch T.J. et al/2010/III | 676               | C +chemotherapy | 64 | 13 | 4.4 | 9.69 | 325 | 0 |
|                 |                      |                   | chemotherapy   | 65                                 | 12                        | 4.24                   | 8.38              | 320             | 2           |
|                 | Govindian R. et al/2011/II | 101              | C+ chemoradiotherapy | 66 | NR | NR | NR | 53 | 3 |
|                 |                      |                   | chemoradiotherapy | 65 | NR | NR | NR | 50 | 2 |
| head and neck cancer | Bonner J.A.et al/2006/III | 424               | C+ radiotherapy | 56 | 8 | 24.4 | 49 | 208 | 0 |
|                 |                      |                   | radiotherapy   | 58                                 | NR                        | 14.9                   | 29.3              | 212             | 0           |
|                 | vermorken J.B. et al/2008/III | 442              | C+ chemotherapy | 56 | 18 | 5.6 | 10.1 | 219 | 10 |
|                 |                      |                   | chemotherapy   | 57                                 | 15                        | 3.3                    | 7.4               | 215             | 7           |
| esophagus carcinoma | Lorenzen S. et al/2009/II | 62                | C+5-FU+DDP    | 61                                 | 16                        | 5.9                    | 9.5               | 32              | 0           |
|                 |                      |                   | 5-FU+DDP      | 62                                 | 12                        | 3.6                    | 5.5               | 30              | 1           |
| pancreatic cancer | Philip A.P. et al/2010/III | 745              | C +GEM        | 64.3                               | NR                        | 3.4                    | 6.3               | 361             | 3           |
|                 |                      |                   | GEM           | 63.7                               | NR                        | 3                      | 5.9               | 355             | 0           |
with cetuximab was higher than that of panitumumab (2.0% versus 0.9%, \( p = 0.007 \)). However, it should be noted that some studies with unusually broad confidence intervals of cetuximab related FAEs were also included for analysis [35,36,39,42], which might indicate less precise results. After excluding these trials, similar incidence of cetuximab related FAEs were observed (1.9%, 95%CI: 1.1-3.0%).

**Odds ratio of FAEs**

To investigate the specific contribution of MoAbs to the development of FAEs and exclude the influence of confounding factors such as underlying malignancy, and other therapeutic interventions, we therefore determined the odds ratio (OR) of MoAbs associated FAEs. The pooled results demonstrated that the use of MoAbs significantly increase the risk of developing FAEs with (Peto OR 1.37, 95%CI: 1.04-1.81, \( p = 0.024 \), Figure 3) using a fixed-effect model \( (I^2 = 0\%, \ p = 0.84) \). As some included trials had a wide variation in confidence intervals, which might decrease the precision of combined results, we thus did sensitivity analysis to examine the stability and reliability of the pooled ORs by sequential omission of individual studies. The results indicated that the significance estimate of pooled ORs was not significantly influenced by omitting any other single study except for the trial conducted by Hecht J.R.[27] (Figure 4). We then performed a meta-regression analysis to test whether the OR of FAEs varied as

| Histology | Authors/ year/phase | Patients enrolled | Treatment Arm | Median age | Median treatment duration (weeks) | Median PFS/TTP (months) | Median OS (months) | No. for analysis | No. of FAEs |
|-----------|---------------------|------------------|---------------|------------|----------------------------------|------------------------|-------------------|----------------|------------|
| MBC       | Baselga J. et al/2013/II | 181              | C +DDP        | 53         | 13.6                             | 3.7                    | 12.9              | 114            | 0          |

Abbreviations: PFS, progression-free survival; OS, overall survival; CRC, colorectal cancer; NSCLC, non-small-cell lung carcinoma; MBC, metastatic breast cancer; FAEs: fatal adverse events; C, cetuximab; P, panitumumab; GEM, gemcitabine; BSC, best support care; L-OHP, oxaliplatin; CPT-11, irinotecan; DDP, cisplatin; Bev, bevacizumab; 5-FU, 5-fluorouracil; NR, not reported.

doi: 10.1371/journal.pone.0081897.t001

![Figure 2. Forest plot for meta-analysis of incidence of FAEs in cancer patients assigned EGFR-MoAbs.](doi: 10.1371/journal.pone.0081897.g002)
function of difference in treatment duration of MoAbs. Since in 8 studies data about treatment duration of MoAbs were not reported, 13 of 21 studies were included in the analysis. Result indicated that there was no significant association between odds ratio and treatment duration of MoAbs (β=0.25; \( p=0.798 \)).

Additionally, sub-group analysis found that the use of cetuximab (OR 1.34, 95%CI: 1.00-1.80, \( p=0.052 \)) and panitumumab (OR 1.66, 95%CI: 0.75-3.71; \( p=0.214 \)) was associated with a non-significant increased risk of FAEs. Then, we explored the risk of FAEs among tumor types, and a non-significantly increased risk of FAEs is observed in CRC, NSCLC, head and neck cancer, and pancreatic cancer, while the risk of FAEs did not increase in metastatic breast cancer and esophagus carcinoma. In addition, the highest OR of FAEs was observed in pancreatic cancer patients with OR of 6.94 (95%CI, 0.36-134.87, \( p=0.731 \)). Of note, the confidence intervals were unusually broad indicating low precision.

Interestingly, there was a significantly increased risk of FAEs in phase III trials (OR 1.40, 95%CI: 1.05-1.85, \( p=0.021 \)), but the risk did not increase in phase II trials (OR 0.95, 95%CI: 0.23-3.67, \( p=0.939 \)) (table 2).

Sensitivity analysis

Sensitivity analyses using an empirical continuity correction [20] (fixed Mantel-Haenszel OR: 1.37, 95%CI: 1.04-1.80), with a continuity of 0.5 correction (fixed Mantel-Haenszel OR: 1.38, 95%CI: 1.04-1.82), or without a continuity correction (fixed Mantel-Haenszel OR: 1.35, 95%CI: 1.03-1.77) showed results similar to those of the primary analysis (table 3).

Publication bias

No evidence of publication bias was detected for the OR of FAEs in this study by either Begg or Egger’s test (OR of FAEs: Begg’s test \( p=0.343 \); Egger’s test \( p=0.071 \)).

Discussion

This meta-analysis provides a comprehensive assessment of the risk of FAEs associated with EGFR-MoAbs. A total of 14,776 patients who received either MoAbs or non-MoAbs regimens are identified from 21 clinical trials. Our pooled results indicate that the overall incidence rate of FAEs is 1.7% (95%CI: 1.1-2.5%). Sub-group analysis demonstrates that the incidence of cetuximab-related FAEs is higher than that of panitumumab (2.0% versus 0.9%). For which we suggest two possible explanations: 1) differences in the distribution of tumor types: in our study, panitumumab is only used in colorectal cancer, while cetuximab has been used in many other tumor types including CRC, NSCLC, or head and neck cancer; 2) relative small patients receive panitumumab therapy, thus the power to detect the incidence of FAEs is low. Additionally, we also demonstrate that there is a small, but significantly increased risk of death with these agents when compared to controls, and sensitivity analysis using different statistical models also confirm our pooled results.

We then perform subgroup analysis to explore the potential risk factors for FAEs. Our study finds that the use of cetuximab and panitumumab is associated with a non-significant increased risk of FAEs. Then, we explore the risk of FAEs...
among tumor types, and a non-significantly increased risk of FAEs is also observed in CRC, NSCLC, head and neck cancer, and pancreatic cancer, while the risk of FAEs does not increase in metastatic breast cancer and esophagus carcinoma. Interestingly, there is a significantly increased risk of FAEs in phase III trials (OR 1.40, 95%CI: 1.05-1.85, \(p=0.021\)), but the risk does not increase in phase II trials (OR 0.95, 95%CI: 0.23-3.87, \(p=0.939\)). There are several possible explanations for these findings: the small number of events recorded; under-reporting of rare adverse events in clinical trials (only 18% of included trials reported FAEs associated with EGFR-MoAbs); the fact that clinical trials are usually not designed specifically to address toxic events; and the small number of trials in other tumor types included. In addition, the meta-regression indicates that there is no significant association between the risk of FAEs and treatment duration of MoAbs (\(\beta=0.25; \ p=0.798\)). Based on our results, we could conclude that the use of EGFR-MoAbs is associated with a

![Figure 4. Meta-analysis of FAEs associated with EGFR-MoAbs versus control: ‘leave-one-out’ sensitivity analysis.](doi: 10.1371/journal.pone.0081897.g004)

Table 2. Incidence and relative risk of FAEs with EGFR-MoAbs according to tumor types, EGFR-MoAbs and phases of trials.

| Groups      | Studies, n | Fatal Adverse Events, No./Total No. | Incidence (95%CI), % | OR (95% CI) | Statistical model | \(P\) value |
|-------------|------------|-------------------------------------|----------------------|-------------|-------------------|------------|
| Overall     | 21         | 119/7841                            | 1.7 (1.1-2.5)        | 1.37 (1.04-1.81) | Fixed             | 0.024      |
| Tumor types |            |                                     |                      |             |                   |            |
| CRC         | 11         | 87/5886                             | 1.6 (0.9-2.7)        | 1.37 (0.99-1.89) | Fixed             | 0.058      |
| NSCLC       | 5          | 19/1021                             | 2.5 (1.1-5.6)        | 1.28 (0.65-2.53) | Fixed             | 0.457      |
| Head and neck cancer | 2  | 10/427                             | 1.4 (0.1-20.5)       | 1.42 (0.54-3.73) | Fixed             | 0.482      |
| EGFR-MoAbs  |            |                                     |                      |             |                   |            |
| Cetuximab   | 17         | 104/6016                            | 2.0 (1.3-3.2)        | 1.34 (1.00-1.80) | Fixed             | 0.052      |
| Panitumab   | 4          | 15/1825                             | 0.9 (0.5-1.7)        | 1.66 (0.75-3.71) | Fixed             | 0.214      |
| Phases of trials |    |                                     |                      |             |                   |            |
| Phase II    | 5          | 4/294                               | 2.8 (1.1-6.7)        | 0.95 (0.23-3.87) | Fixed             | 0.939      |
| Phase III   | 16         | 115/7547                            | 1.6 (1.0-2.5)        | 1.40 (1.05-1.85) | Fixed             | 0.021      |

Abbreviations: NSCLC, non-small-cell lung cancer; CRC, colorectal cancer; OR, odds ratio.

doi: 10.1371/journal.pone.0081897.t002
significantly increased risk of developing FAEs in cancer patients, and the risk of FAEs is not associated with the treatment duration of MoAbs therapies.

Our meta-analysis has some limitations. First, this is a meta-analysis based on published data, and confounding variables at the patient level, such as co-morbidities, concomitant medications, specific age and previous therapies could not be incorporated into the analysis. Another limitation was that all of the included studies were conducted in patients with adequate organ function at study entry, suggesting that rates of FAEs could be higher in common practice. Also the process by which individual clinicians in trials determined whether a patient’s death was the result of a study drug, cancer progression or other unrelated causes carried some subjectivity and was a potential source of bias. Additionally, different treatment strategy, duration, and regimens contributed to increase the clinical heterogeneity of the meta-analysis, which made the interpretation of the meta-analysis more problematic, although we performed sub-group analysis and sensitivity analysis. And it is possible that the concomitant administration of other drugs (such as the combination of cetuximab and bevacizumab) in a few of the trials may have contributed to a higher risk of FAEs.

In conclusion, the use of EGFR-MoAbs therapies is associated with a small, but significant increase in the risk of fatal drug-related events. Despite these findings, both cetuximab and panitumumab benefit the overall population of patients with clear FDA-approved indications. As this class of drugs gains greater clinical use, clinicians should be aware of the risks associated with their use and should monitor closely and appropriately use strategies to improve patient outcomes.

Supporting Information

Checklist S1. (DOC)

Author Contributions

Conceived and designed the experiments: XL Z-YW. Performed the experiments: B-ES JW L-PX. Analyzed the data: X-JG Y-HZ XL. Contributed reagents/materials/analysis tools: PHS XL ZYW. Wrote the manuscript: XL ZYW.

References

1. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102: 37-46. doi: 10.1016/j.pharmthera.2004.01.002. PubMed: 15086497.

2. Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijken G (1998) Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425: 145-150. doi: 10.1016/S0014-5793(98)00244-5. PubMed: 9541025.

3. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P et al. (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15: 28-32. doi: 10.1093/annonc/mdh011. PubMed: 14679115.

4. Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y et al. (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36: 1127-1134. doi: 10.1016/j.humpath.2005.08.007. PubMed: 16226114.

5. Ikatuya, Sasan H, Shiga C, Furukawa Y, Shiga K et al. (1994) Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804. doi: 10.1002/1097-0142(19940810)74:3<803::AID-CNCR22>3.0.CO;2-E. PubMed: 8039107.

6. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S et al. (2006) Mutant epidermal growth factor receptor (EGFRVIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12: 5064-5073. doi: 10.1158/1078-0432.CCR-06-0913. PubMed: 16951222.

7. Kari C, Chan TO, Rocha de Quadros M, Rodeck U (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63: 1-5. PubMed: 12517767.

8. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799. doi: 10.1200/JCO.2003.01.504. PubMed: 12860957.

9. Cohenram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18: 7-15. doi: 10.1097/CAD.0b013e32800f0eb3. PubMed: 17159497.

10. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10: 461-466. doi: 10.1634/theoncologist.10-7-461. PubMed: 16079312.

11. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306. doi: 10.1634/theoncologist.8-4-303. PubMed: 12897327.

12. Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Curr Ther Res 70: 684-694. doi: 10.1016/j.clithea.2005.06.003. PubMed: 16117976.

13. Oldham RK, Dillman R (2008) Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 26: 1774-1777. doi: 10.1200/JCO.2007.15.7436. PubMed: 18398141.

14. Schutz FA, Je Y, Richards CJ, Choueiri TK (2012) Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30: 871-877. doi: 10.1200/JCO.2011.37.1195. PubMed: 22312105.

15. Qi WX, Tang LN, He AN, Yao Y, Shen Z (2013) Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: A meta-analysis of 22 phase III randomized controlled trials. Respir Med 107: 1280-1283. doi: 10.1016/j.rmed.2013.06.005. PubMed: 23810298.

16. Zhang D, Ye J, Xu T, Xiong B (2013) Treatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysis. J Chemother 25: 170-175. doi: 10.1179/1973947813Y.0000000070. PubMed: 23783142.

17. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535. doi: 10.1136/bmj.b2535. PubMed: 19622551.

18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6: e1000097.

19. NCI, Cancer Therapy Evaluation Program. CTC v 2.0 and common terminology criteria for adverse events version V3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm assessed Jan 27 2013.

20. Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse
data. Stat Med 23: 1351-1375. doi:10.1002/sim.1761. PubMed: 19116387.
21. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137. doi:10.1002/gepi.20048. PubMed: 15953093.
22. Yusuf S, Pepine CJ, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371. doi:10.1016/S0033-0620(85)80003-7. PubMed: 2858114.
23. Beig CG, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1110. doi:10.2307/2533446. PubMed: 7786990.
24. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendizzi A et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664. doi:10.1200/JCO.2006.16.1820. PubMed: 17470858.
25. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319. doi:10.1200/JCO.2007.13.1193. PubMed: 18390971.
26. Bokemeyer C, Bondarenko I, Markson A, Hartmann JT, Aparicio J et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with or without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671. doi:10.1200/JCO.2008.20.8397. PubMed: 19114685.
27. Hecht JR, Mitchell E, Chidac T, Scrogg C, Hagenstad C et al. (2009) A randomized phase IIIB trial of chemotherapy, bevazucizumab, and panitumumab compared with chemotherapy and bevazucizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680. doi:10.1200/JCO.2008.19.8135. PubMed: 19114685.
28. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. Lancet 374: 1408-1417. doi:10.1016/S0140-6736(09)60569-9. PubMed: 19393720.
29. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFIRX) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705. doi:10.1200/JCO.2009.27.4860. PubMed: 20921465.
30. Peeters M, Price TJ, Cervantes A, Sobro A, Ducreux M et al. (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, irinotecan (FOLFIRI) compared with FOLFIrI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713. doi:10.1200/JCO.2009.27.6055. PubMed: 20921462.
31. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-2114. doi:10.1016/S0140-6736(11)60613-2. PubMed: 21641636.
32. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M et al. (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307: 1383-1393. doi:10.1001/jama.2012.385. PubMed: 22474202.
33. Saltz L, Badarath S, Dakhil S, Bienvenu B, Harker WG et al. (2012) Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 11: 101-111. doi:10.1016/j.ccc.2011.05.006. PubMed: 22055112.
34. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572. doi:10.1056/NEJMoa0806268. PubMed: 19196873.
35. Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D et al. (2007) Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer. J Clin Oncol 25: 5777-5784. doi:10.1200/JCO.2007.13.0856. PubMed: 18088785.
36. Lilenbaum R, Wang X, Gu L, Kirshner J, Lenro K et al. (2009) Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 27: 4487-4491. doi:10.1200/JCO.2009.22.7066. PubMed: 19704058.
37. Pirker R, Pereira JR, Szczesna A, von Pawel J, Kraszokowski M et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531. doi:10.1016/S0140-6736(09)60569-9. PubMed: 19410716.
38. Lynch TJ, Patel T, Dreisbach M, McCleod M, Heim WJ et al. (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28: 911-917. doi:10.1200/JCO.2009.21.9618. PubMed: 20100966.
39. Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L et al. (2011) Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced, unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 29: 3120-3125. doi:10.1200/JCO.2010.33.4979. PubMed: 21747084.
40. Bonner JA, Harani PM, Giralt J, Azamia N, Shin DM et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578. doi:10.1056/NEJMoa053422. PubMed: 18467544.
41. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127. doi:10.1056/NEJMoa0802656. PubMed: 18784101.
42. Lorenzen S, Schuster T, Porsche R, Al-Batran SE, Hofheinz R et al. (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5- fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische. Onkologie - Ann Oncol 20: 1667-1673. doi:10.1093/annonc/mdp0869.
43. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM et al. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610. doi:10.1200/JCO.2009.25.7550. PubMed: 20606093.
44. Basega J, Gomez P, Greil R, Braga S, Climent MA et al. (2013) Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative. Breast Cancer - J Clin Oncol.